Related Experiment Video

Updated: May 16, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Deep brain stimulation in Parkinson's disease: reconciliation of evidence-based medicine with clinical practice

Paul Krack1, Marwan I Hariz

  • 1Department of Psychiatry and Neurology, University Hospital of Grenoble, 38043 Grenoble, France. paul.krack@ujf-grenoble.fr

The Lancet. Neurology
|November 22, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
06:32

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation

Published on: July 14, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
06:32

Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation

Published on: July 14, 2023

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Articles linked to this work by shared authors, journal, and citation graph.

Dopaminergic state modulates shame and contextual emotional responses in Parkinson's disease.

Journal of Parkinson's disease·2026

Understanding Neuropsychiatric Fluctuations in Parkinson's Disease: From Mechanisms to Management.

Movement disorders clinical practice·2026

Decoding Sleep Architecture from Ambulatory Basal Ganglia Signals in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction-relevant mechanisms.

Psychiatry and clinical neurosciences·2026

Speech Biomarkers for Quantifying Effects of Subthalamic Deep Brain Stimulation in Parkinson's Disease.

Annals of neurology·2026

Subperception dorsal root ganglion stimulation versus sham stimulation in established responders: a randomized, double-blind crossover clinical trial.

Regional anesthesia and pain medicine·2026

Degenerative cervical myelopathy: early detection and the potential for preventing disability.

The Lancet. Neurology·2026

Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study.

The Lancet. Neurology·2026

Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.

The Lancet. Neurology·2026

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

The Lancet. Neurology·2026

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

The Lancet. Neurology·2026

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

The Lancet. Neurology·2026

[Pharmacokinetics of three main components of Angelicae Dahuricae Radix and Chuanxiong Rhizoma herb pair compatibility in rats].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026

Overcoming Hyperkalaemia to Optimise Heart Failure Therapy: The Emerging Role of Novel Potassium Binders.

Cardiac failure review·2026

Assessing the use of ASAP-MS for Screening a UK Pub for Illicit Drug Substances.

Journal of mass spectrometry : JMS·2026

Angiotensin peptide and aldosterone concentrations in response to four classes of blood-pressure-lowering drugs in hypertensive patients: A randomized trial.

Journal of human hypertension·2026

PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides.

Annals of nuclear medicine·2026

Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.

Sexual medicine reviews·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us